Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TJ011133 plus azacitidine in untreated AML or higher-risk MDS
CTR20210555Phase 2Completed
- Sponsor
- Tianjing Biopharma
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of lemzoparlimab in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Tianjing Biopharma. Started Mar 2021; status: completed.
02
Drugs
lemzoparlimab
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on CTR20210555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210555.